drugset
drugset / Trial / NCT00404339

Vaccine Therapy in Treating Patients With Head and Neck Cancer

NCT00404339 ↗

Phase 1 Completed 17 enrolled Robert Ferris National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelTreatment

Summary

RATIONALE: Vaccines made from a person's dendritic cells mixed with peptides may help the body build an effective immune response to kill tumor cells. PURPOSE: This randomized phase I trial is studying the side effects of vaccine therapy in treating patients with head and neck cancer.

Timeline

Start
2005-09
Primary completion
2011-03
Completion
2014-03

Drugs

EvaluationDrugModalityDoseRoute
Subject mutant p53 peptide pulsed dendritic cell vaccine Vaccine — Other
Subject tetanus toxoid helper peptide Peptide — Other

Indications

head and neck cancer